Total
0
Shares
Paradigm Biopharmaceuticals (ASX:PAR) - CEO & Acting Chair, Paul Rennie
CEO & Acting Chair, Paul Rennie
Source: The Advertiser
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Paradigm Biopharmaceuticals (PAR) submits its response to the US Food and Drug Administration (FDA) in relation to its knee osteoarthritis study
  • In preparing the response, Paradigm consulted with multiple experts to review the document and ensure it contains sufficient information
  • Paradigm believes that the input from these experts will increase its likelihood that it will meet the requirements of the FDA
  • The FDA will now review this response over the next 30 days
  • Just before the market opens this morning, Paradigm is trading at $1.94

Paradigm Biopharmaceuticals (PAR) has submitted its response to the US Food and Drug Administration (FDA) in relation to its knee osteoarthritis study.

Last month, the company received written feedback from the FDA, which included questions in relation to recently completed non-clinical studies evaluating pentosan polysulfate sodium (PPS) in knee osteoarthritis.

In preparing the response, Paradigm consulted with multiple experts to review the document and ensure it contains sufficient information.

Paradigm believes that the input from these experts will increase its likelihood that it will meet the requirements of the FDA.

The FDA will now review this response over the next 30 days.

“We have responded to the FDA’s questions following diligent reviews with our Internal team and consultants,” CMO Dr Donna Skerrett said.

“We believe these responses are sufficient to assure the agency the program is supported by non-clinical and clinical data and that the objectives, rationale, and study design will aim to demonstrate the safety and effectiveness of PPS for patients with painful osteoarthritis of the knee.

“There is a clear unmet need for patients who have not had adequate responses
to initial therapy for knee OA and have ongoing pain. Prior experience with PPS in clinical and non-clinical settings has demonstrated the potential to address this unmet need.”

Just before the market opens this morning, Paradigm is trading at $1.94.

PAR by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).